Skip to content

Nabla Bio

YC S20 · Active · We use AI to design antibodies for intractable diseases

Competitors

Adjacent

Also from S20 in AI

All of S20

About Nabla Bio

Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.

YC batch
S20 · Summer 2020
Status, per YC
Active
Category
AI
Team size
8
Location
Boston, MA, USA
Checked
35m ago

YC tags: AI-powered Drug Discovery

Nabla Bio in S20: 209 companies, 28% AI

Nabla Bio: questions

Which YC batch was Nabla Bio in?

Nabla Bio was in Y Combinator's Summer 2020 batch (S20).

Is Nabla Bio still active?

Y Combinator lists Nabla Bio as active.

Where is Nabla Bio based?

Nabla Bio lists Boston, MA, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.